FDMT
4D Molecular Therapeutics, Inc.
Price Chart
Latest Quote
$11.52
+0.49 (+4.44%)
Current Price
| Previous Close | $11.03 |
| Open | $10.96 |
| Day High | $11.52 |
| Day Low | $10.75 |
| Volume | 117,894 |
Stock Information
| Shares Outstanding | 55.24M |
| Total Debt | $39.22M |
| Cash Equivalents | $361.33M |
| Revenue | $92.01M |
| Net Income | $-179.18M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $660.72M |
| EPS (TTM) | $-2.63 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $287.23M |
| Sales | $92.01M |
| Income | $-179.18M |
| Book/sh | $7.38 |
| Cash/sh | $6.54 |
| Employees | 196 |
Financial Ratios
| Quick Ratio | 7.68 |
| Current Ratio | 8.03 |
| Debt/Eq | 9.62 |
Returns & Margins
| ROA | -25.09% |
| ROE | -43.25% |
| Gross Margin | -157.70% |
| Operating Margin | -2037.16% |
| Profit Margin | -194.74% |
Ownership
| Insider Ownership | 2.72% |
| Institutional Ownership | 106.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.92 |
| P/S | 7.18 |
| P/B | 1.62 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $28.09 |
Technical Indicators
| SMA20 | $12.61 |
| SMA50 | $13.91 |
| SMA200 | $10.81 |
| RSI | 45.90 |
| ATR | 0.9084 |
| Shares Float | 42.55M |
| Short Float | 23.32% |
| Short Ratio | 11.58 |
| Volatility | 2.74 |
| Rel Volume | 1.09 |
Performance History
| Week | -8.70% |
| Month | -17.86% |
| Quarter | +24.45% |
| 6 Months | +26.96% |
| YTD | +63.39% |
| Year | +5.47% |
| 3 Years | +18.18% |
| 5 Years | -62.59% |
| 10 Years | -70.47% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $11.96 | 1,127,146 |
| 2026-10-26 | $11.03 | 1,084,600 |
| 2026-10-23 | $10.80 | 996,100 |
| 2026-10-22 | $11.85 | 1,354,700 |
| 2026-10-21 | $12.62 | 2,019,200 |
| 2026-10-20 | $13.10 | 725,400 |
| 2026-10-19 | $12.29 | 855,700 |
| 2026-10-16 | $12.14 | 794,500 |
| 2026-10-15 | $12.87 | 787,600 |
| 2026-10-14 | $12.20 | 633,000 |
| 2026-10-13 | $12.36 | 991,700 |
| 2026-10-12 | $13.00 | 835,800 |
| 2026-10-09 | $13.33 | 867,900 |
| 2026-10-08 | $12.70 | 970,800 |
| 2026-10-07 | $12.59 | 603,600 |
| 2026-10-06 | $12.56 | 1,170,900 |
| 2026-10-05 | $12.92 | 2,110,300 |
| 2026-10-02 | $13.67 | 1,036,900 |
| 2026-10-01 | $13.84 | 655,500 |
| 2026-09-30 | $14.31 | 1,037,100 |
| 2026-09-29 | $14.49 | 1,376,000 |
| 2026-09-28 | $14.56 | 1,557,400 |
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on FDMT.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $85,209,000 | $37,000 | $20,723,000 | $3,129,000 |
| Operating Revenue | $85,209,000 | $37,000 | $20,723,000 | $3,129,000 |
| Expenses | ||||
| Total Expenses | $244,756,000 | $187,878,000 | $133,590,000 | $113,161,000 |
| Other Income Expense | $-37,000 | $-77,000 | $-181,000 | $-35,000 |
| Other Non Operating Income Expenses | $-37,000 | $-77,000 | $-181,000 | $-35,000 |
| Net Non Operating Interest Income Expense | $19,475,000 | $27,050,000 | $12,211,000 | $2,573,000 |
| Operating Expense | $244,756,000 | $187,878,000 | $133,590,000 | $113,161,000 |
| General And Administrative Expense | $49,060,000 | $46,579,000 | $36,494,000 | $32,908,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Interest Income | $19,475,000 | $27,050,000 | $12,211,000 | $2,573,000 |
| Interest Income | $19,475,000 | $27,050,000 | $12,211,000 | $2,573,000 |
| Normalized Income | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Income From Continuing And Discontinued Operation | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Total Operating Income As Reported | $-159,547,000 | $-187,841,000 | $-112,867,000 | $-110,032,000 |
| Net Income Common Stockholders | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Income | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Income Including Noncontrolling Interests | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Net Income Continuous Operations | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Pretax Income | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Interest Income Non Operating | $19,475,000 | $27,050,000 | $12,211,000 | $2,573,000 |
| Operating Income | $-159,547,000 | $-187,841,000 | $-112,867,000 | $-110,032,000 |
| Per Share | ||||
| Diluted EPS | $-2.42 | $-2.98 | $-2.58 | $-3.32 |
| Basic EPS | $-2.42 | $-2.98 | $-2.58 | $-3.32 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-151,922,000 | $-181,136,000 | $-107,118,000 | $-106,152,000 |
| Reconciled Depreciation | $7,625,000 | $6,705,000 | $5,749,000 | $3,880,000 |
| EBITDA (Bullshit earnings) | $-151,922,000 | $-181,136,000 | $-107,118,000 | $-106,152,000 |
| EBIT | $-159,547,000 | $-187,841,000 | $-112,867,000 | $-110,032,000 |
| Diluted Average Shares | $57,930,180 | $53,943,741 | $39,130,067 | $32,351,221 |
| Basic Average Shares | $57,930,180 | $53,943,741 | $39,130,067 | $32,351,221 |
| Diluted NI Availto Com Stockholders | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Research And Development | $195,696,000 | $141,299,000 | $97,096,000 | $80,253,000 |
| Selling General And Administration | $49,060,000 | $46,579,000 | $36,494,000 | $32,908,000 |
| Other Gand A | $49,060,000 | $46,579,000 | $36,494,000 | $32,908,000 |
Fetched: 2026-10-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Total Assets | $566,711,000 | $560,384,000 | $339,891,000 | $261,846,000 |
| Total Non Current Assets | $153,577,000 | $125,452,000 | $43,303,000 | $41,335,000 |
| Other Non Current Assets | $9,188,000 | $4,261,000 | $684,000 | $1,080,000 |
| Investmentin Financial Assets | $111,379,000 | $80,583,000 | $10,954,000 | $4,908,000 |
| Current Assets | $413,134,000 | $434,932,000 | $296,588,000 | $220,511,000 |
| Other Current Assets | $10,479,000 | $10,055,000 | $8,356,000 | $6,957,000 |
| Cash Cash Equivalents And Short Term Investments | $402,655,000 | $424,877,000 | $288,232,000 | $213,554,000 |
| Cash And Cash Equivalents | $60,241,000 | $149,336,000 | $249,108,000 | $52,351,000 |
| Receivables | - | - | - | $0 |
| Accounts Receivable | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $21,413,000 | $24,606,000 | $14,671,000 | $16,124,000 |
| Long Term Debt And Capital Lease Obligation | $15,821,000 | $18,969,000 | $11,522,000 | $13,469,000 |
| Current Debt And Capital Lease Obligation | $5,592,000 | $5,637,000 | $3,149,000 | $2,655,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $61,047,000 | $49,778,000 | $32,062,000 | $30,509,000 |
| Total Non Current Liabilities Net Minority Interest | $17,062,000 | $20,629,000 | $13,111,000 | $14,778,000 |
| Other Non Current Liabilities | $138,000 | $193,000 | $248,000 | $21,000 |
| Derivative Product Liabilities | $358,000 | $410,000 | $369,000 | $212,000 |
| Non Current Deferred Liabilities | $745,000 | $1,057,000 | $972,000 | $1,076,000 |
| Current Liabilities | $43,985,000 | $29,149,000 | $18,951,000 | $15,731,000 |
| Current Deferred Liabilities | $360,000 | $257,000 | $273,000 | $884,000 |
| Payables And Accrued Expenses | $38,033,000 | $23,255,000 | $15,529,000 | $12,192,000 |
| Payables | $11,159,000 | $4,386,000 | $3,515,000 | $3,322,000 |
| Accounts Payable | $11,159,000 | $4,386,000 | $3,515,000 | $3,322,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Total Equity Gross Minority Interest | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Stockholders Equity | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Gains Losses Not Affecting Retained Earnings | $727,000 | $229,000 | $16,000 | $-1,196,000 |
| Other Equity Adjustments | $727,000 | $229,000 | $16,000 | $-1,196,000 |
| Retained Earnings | $-716,304,000 | $-576,195,000 | $-415,327,000 | $-314,490,000 |
| Other | ||||
| Ordinary Shares Number | $57,607,874 | $45,793,942 | $43,075,218 | $32,626,627 |
| Share Issued | $57,607,874 | $45,793,942 | $43,075,218 | $32,626,627 |
| Tangible Book Value | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Invested Capital | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Working Capital | $369,149,000 | $405,783,000 | $277,637,000 | $204,780,000 |
| Capital Lease Obligations | $21,413,000 | $24,606,000 | $14,671,000 | $16,124,000 |
| Total Capitalization | $505,664,000 | $510,606,000 | $307,829,000 | $231,337,000 |
| Additional Paid In Capital | $1,221,235,000 | $1,086,567,000 | $723,136,000 | $547,020,000 |
| Capital Stock | $6,000 | $5,000 | $4,000 | $3,000 |
| Common Stock | $6,000 | $5,000 | $4,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $745,000 | $1,057,000 | $972,000 | $1,076,000 |
| Long Term Capital Lease Obligation | $15,821,000 | $18,969,000 | $11,522,000 | $13,469,000 |
| Current Deferred Revenue | $360,000 | $257,000 | $273,000 | $884,000 |
| Current Capital Lease Obligation | $5,592,000 | $5,637,000 | $3,149,000 | $2,655,000 |
| Current Accrued Expenses | $26,874,000 | $18,869,000 | $12,014,000 | $8,870,000 |
| Investments And Advances | $111,379,000 | $80,583,000 | $10,954,000 | $4,908,000 |
| Available For Sale Securities | $111,379,000 | $80,583,000 | $10,954,000 | $4,908,000 |
| Net PPE | $33,010,000 | $40,608,000 | $31,665,000 | $35,347,000 |
| Accumulated Depreciation | $-21,279,000 | $-16,585,000 | $-11,932,000 | $-7,728,000 |
| Gross PPE | $54,289,000 | $57,193,000 | $43,597,000 | $43,075,000 |
| Leases | $18,467,000 | $17,763,000 | $16,902,000 | $16,902,000 |
| Construction In Progress | $0 | $1,182,000 | $550,000 | $476,000 |
| Machinery Furniture Equipment | $17,679,000 | $17,174,000 | $14,606,000 | $12,612,000 |
| Buildings And Improvements | $18,143,000 | $21,074,000 | $11,539,000 | $13,085,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $342,414,000 | $275,541,000 | $39,124,000 | $161,203,000 |
| Other Properties | - | - | $11,539,000 | $13,085,000 |
Fetched: 2026-10-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-109,618,000 | $-138,371,000 | $-78,563,000 | $-98,221,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-109,082,000 | $-134,585,000 | $-75,792,000 | $-86,685,000 |
| Cash Flow From Continuing Operating Activities | $-109,082,000 | $-134,585,000 | $-75,792,000 | $-86,685,000 |
| Operating Gains Losses | $-52,000 | $107,000 | $245,000 | $85,000 |
| Investing Activities | ||||
| Capital Expenditure | $-536,000 | $-3,786,000 | $-2,771,000 | $-11,536,000 |
| Investing Cash Flow | $-92,973,000 | $-302,437,000 | $115,717,000 | $-17,050,000 |
| Cash Flow From Continuing Investing Activities | $-92,973,000 | $-302,437,000 | $115,717,000 | $-17,050,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $110,723,000 | $331,412,000 | $148,344,000 | $0 |
| Financing Cash Flow | $112,960,000 | $337,250,000 | $156,832,000 | $3,085,000 |
| Cash Flow From Continuing Financing Activities | $112,960,000 | $337,250,000 | $156,832,000 | $3,085,000 |
| Net Common Stock Issuance | $110,723,000 | $331,412,000 | $148,344,000 | $0 |
| Common Stock Issuance | $110,723,000 | $331,412,000 | $148,344,000 | $0 |
| Net Other Financing Charges | - | - | - | $-468,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $60,241,000 | $149,336,000 | $249,108,000 | $52,351,000 |
| Beginning Cash Position | $149,336,000 | $249,108,000 | $52,351,000 | $153,001,000 |
| Changes In Cash | $-89,095,000 | $-99,772,000 | $196,757,000 | $-100,650,000 |
| Proceeds From Stock Option Exercised | $2,237,000 | $5,838,000 | $8,488,000 | $3,553,000 |
| Net Investment Purchase And Sale | $-92,437,000 | $-298,651,000 | $118,488,000 | $-5,514,000 |
| Sale Of Investment | $350,384,000 | $169,001,000 | $173,290,000 | $147,799,000 |
| Purchase Of Investment | $-442,821,000 | $-467,652,000 | $-54,802,000 | $-153,313,000 |
| Net PPE Purchase And Sale | $-536,000 | $-3,786,000 | $-2,771,000 | $-11,536,000 |
| Purchase Of PPE | $-536,000 | $-3,786,000 | $-2,771,000 | $-11,536,000 |
| Change In Working Capital | $6,172,000 | $537,000 | $630,000 | $-1,336,000 |
| Change In Other Working Capital | $-209,000 | $69,000 | $-715,000 | $-3,130,000 |
| Change In Other Current Liabilities | $-3,193,000 | $-1,651,000 | $-1,453,000 | $-324,000 |
| Change In Other Current Assets | $-4,927,000 | $-3,577,000 | $-70,000 | $-11,000 |
| Change In Payables And Accrued Expense | $14,925,000 | $7,395,000 | $4,267,000 | $847,000 |
| Change In Accrued Expense | $8,152,000 | $6,524,000 | $3,371,000 | $2,485,000 |
| Change In Payable | $6,773,000 | $871,000 | $896,000 | $-1,638,000 |
| Change In Account Payable | $6,773,000 | $871,000 | $896,000 | $-1,638,000 |
| Change In Prepaid Assets | $-424,000 | $-1,699,000 | $-1,399,000 | $1,235,000 |
| Stock Based Compensation | $22,016,000 | $26,116,000 | $19,665,000 | $17,121,000 |
| Amortization Of Securities | $-4,734,000 | $-7,182,000 | $-1,244,000 | $1,059,000 |
| Depreciation Amortization Depletion | $7,625,000 | $6,705,000 | $5,749,000 | $3,880,000 |
| Depreciation And Amortization | $7,625,000 | $6,705,000 | $5,749,000 | $3,880,000 |
| Depreciation | $7,625,000 | $6,705,000 | $5,749,000 | $3,880,000 |
| Gain Loss On Investment Securities | $-52,000 | $107,000 | $245,000 | $85,000 |
| Net Income From Continuing Operations | $-140,109,000 | $-160,868,000 | $-100,837,000 | $-107,494,000 |
| Change In Receivables | - | - | $0 | $47,000 |
| Changes In Account Receivables | - | - | $0 | $47,000 |
Fetched: 2026-10-18